Insuficiencia cardíaca con fracción de eyección ligeramente reducida. Retos, realidades y futuro
DOI:
https://doi.org/10.18041/2665-427X/ijeph.2.9885Palabras clave:
Insuficiencia Cardíaca, Imagen por Resonancia Magnética, Inhibidores del Cotransportador de Sodio-Glucosa 2, EcocardiografíaResumen
Introducción: La insuficiencia cardiaca con fracción de eyección ligeramente reducida ha sido a lo largo de su historia un punto sensible en la cardiología ya que ha tenido múltiples denominaciones y una fisiopatología que puede pertenecer tanto a la insuficiencia cardiaca con fracción de eyección menor al 40% como la que tiene fracción de eyección mayor al 50%, lo que ha dificultado generar unas recomendaciones estándar para esta entidad
Objetivo: Reconocer a la insuficiencia cardiaca ligeramente reducida como una entidad individual tanto para su diagnóstico y seguimiento, para la cual en la actualidad se vienen tratando de desarrollar fenotipos que nos permitan ir más allá de la fracción de eyección, principalmente consolidados a partir de características valoradas por resonancia magnética cardiaca, como para su manejo.
Metodos: Revisión narrativa de la literatura
Resultados: Las terapéuticas tradicionales como Betabloqueadores, IECAS/ARAII, Antagonistas del receptor mineralocorticoide apenas logran dar lugar en guías a su uso por consideración médica (Recomendación IIb), como novedad tenemos los iSGLT2 que se vienen posicionando como la terapéutica estándar en el síndrome de falla cardiaca sin importar la fracción de eyección del ventrículo izquierdo.
Descargas
Referencias
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021; 27:387-413. Doi: 10.1016/j.cardfail.2021.01.022.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98. Doi: 10.1056/NEJMoa2206286.
Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21:1279-87. Doi: 10.1002/ejhf.1596.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-28. Doi: 10.1056/NEJMoa2030183.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147-239. Doi: 10.1016/j.jacc.2013.05.019.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200. Doi: 10.1093/eurheartj/ehw128.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19:1586-96. Doi: 10.1002/ejhf.798.
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100-16. Doi: 10.1038/s41569-021-00605-5.
Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail. 2017;19:1569-73. Doi: 10.1002/ejhf.1058.
Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017;19:1597-605. Doi: 10.1002/ejhf.879.
Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721-30. Doi: 10.1016/j.ahj.2014.07.008.
Coles AH, Tisminetzky M, Yarzebski J, Lessard D, Gore JM, Darling CE, et al. Magnitude of and Prognostic Factors Associated With 1-Year Mortality After Hospital Discharge for Acute Decompensated Heart Failure Based on Ejection Fraction Findings. J Am Heart Assoc. 2015;4:e002303. Doi: 10.1161/JAHA.115.002303.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726. Doi: 10.1093/eurheartj/ehab368.
Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-51. Doi: 10.1016/j.jacc.2011.09.062.
Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987;31:1402-15. Doi: 10.1038/ki.1987.156.
Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984; 101(3): 370-7.
doi: 10.7326/0003-4819-101-3-370.
Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431-44. Doi: 10.1172/JCI31060.
Bhargava V, Shabetai R, Mathiäsen RA, Dalton N, Hunter JJ, Ross J. Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol. 1998;81:1130-7. Doi: 10.1016/s0002-9149(98)00133-7.
Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res. 1994;28:1863-7. Doi: 10.1093/cvr/28.12.1863.
Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865-79. Doi: 10.1006/jmcc.2000.1129.
Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624-34. Doi: 10.1002/ejhf.945.
Kim Y-J, Kim RJ. The role of cardiac MR in new-onset heart failure. Curr Cardiol Rep. 2011;13:185-93. Doi: 10.1007/s11886-011-0179-0.
Quarta G, Gori M, Iorio A, D'Elia E, Moon JC, Iacovoni A, et al. Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. Eur J Heart Fail. 2020;22:1065-75. Doi: 10.1002/ejhf.1961.
Treibel TA, Kozor R, Schofield R, Benedetti G, Fontana M, Bhuva AN, et al. Reverse Myocardial Remodeling Following Valve Replacement in Patients With Aortic Stenosis. J Am Coll Cardiol. 2018;71:860-71. Doi: 10.1016/j.jacc.2017.12.035.
Plata-Mosquera CA, Bernal-Tórres W, Herrera-Escandón ÁA, Uribe-Posso LP, Rodríguez-Casanova ÁM, Casanova-Valderrama ME, et al. Sacubitril/valsartan reduces levels of procollagen types I and III and correlates with reverse cardiac remodeling. REC CardioClinics. 2021;56:14-21. Doi: 10.1016/j.rccl.2020.06.002.
Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43-51. Doi: 10.1016/j.ahj.2004.03.004.
Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25. Doi: 10.1093/eurheartj/ehi115.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81. Doi: 10.1016/S0140-6736(03)14285-7.
Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2014;370:1383-92. Doi: 10.1056/NEJMoa1313731.
Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin inhibition in Heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-20. Doi: 10.1056/NEJMoa1908655.
Bozkurt B, Fonarow GC, Goldberg LR, Guglin M, Josephson RA, Forman DE, et al. Cardiac rehabilitation for patients with heart failure: JACC Expert Panel. J Am Coll Cardiol. 2021;77:1454-69. Doi: 10.1016/j.jacc.2021.01.030.
Publicado
Versiones
- 2023-03-15 (3)
- 2023-03-13 (2)
- 2022-12-30 (1)
Número
Sección
Licencia
Derechos de autor 2022 Interdisciplinary Journal of Epidemiology and Public Health
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
